Renaissance Technologies LLC Has $242.34 Million Position in Medpace Holdings, Inc. $MEDP

Renaissance Technologies LLC grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 8.3% in the first quarter, HoldingsChannel.com reports. The fund owned 504,668 shares of the company’s stock after acquiring an additional 38,760 shares during the period. Renaissance Technologies LLC’s holdings in Medpace were worth $242,337,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Geneos Wealth Management Inc. grew its holdings in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. acquired a new stake in Medpace in the fourth quarter worth $30,000. Elyxium Wealth LLC acquired a new stake in Medpace in the fourth quarter worth $30,000. Quarry LP bought a new position in shares of Medpace during the third quarter worth $35,000. Finally, Bayban acquired a new position in shares of Medpace in the 4th quarter valued at $44,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on MEDP shares. Leerink Partners set a $620.00 price objective on shares of Medpace in a research report on Thursday. Truist Financial boosted their target price on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research note on Friday. Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. TD Cowen raised their price target on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday. Finally, Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and lifted their price objective for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Two research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $560.92.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article
• Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article
• Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article
• Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article
• Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article

Medpace Stock Down 0.7%

Shares of NASDAQ:MEDP opened at $601.38 on Friday. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The company’s fifty day simple moving average is $492.09 and its 200 day simple moving average is $494.49. The firm has a market cap of $17.18 billion, a price-to-earnings ratio of 35.25, a PEG ratio of 2.96 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts expect that Medpace Holdings, Inc. will post 17.45 earnings per share for the current fiscal year.

Insider Activity at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 20.50% of the stock is currently owned by company insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.